Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series

OBJECTIVE: Rituximab is a CD20-directed cytolytic antibody used for non-Hodgkin lymphoma, chronic lymphocytic leukaemia and RA, and off label for JIA, multiple sclerosis and lupus. Owing to concerns about infant B cell depletion, the manufacturer recommends avoidance of rituximab throughout pregnanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrotta, Kirstie, Kiernan, Elizabeth, Bandoli, Gretchen, Manaster, Rachel, Chambers, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819866/
https://www.ncbi.nlm.nih.gov/pubmed/33521513
http://dx.doi.org/10.1093/rap/rkaa074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819866/
https://www.ncbi.nlm.nih.gov/pubmed/33521513
http://dx.doi.org/10.1093/rap/rkaa074

Ejemplares similares